On March 27, 2014, Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced the presentation of preliminary data from the Phase 1/2 study of recombinant human beta-glucuronidase (rhGUS, UX003), an investigational therapy for the treatment of mucopolysaccharidosis (MPS 7, sly syndrome). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares after opening at $37.56 moved to $37.56 on last trade day and at the end of the day closed at $35.25.Company price to cash ratio as 16.65. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a negative weekly performance of -17.18%.
On Apr 23, 2014 Acceleron Pharma Inc (NASDAQ:XLRN) announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis. The data are from an ongoing phase 2a study of sotatercept and were presented at the National Kidney Foundation 2014 Spring Clinical Meeting in Las Vegas, NV. Acceleron Pharma Inc (NASDAQ:XLRN) shares advanced 2.04% in last trading session and ended the day on $32.50. XLRN return on equity ratio is recorded as 37.10% and its return on assets is -48.80%.
On April 15,2014 Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in combination with the DNA methylation inhibitor decitabine (Dacogen(R)) in patients with relapsed or refractory acute myeloid leukemia (AML) and in patients age >=60 years with newly diagnosed AML. The study is being conducted at The Ohio State University Comprehensive Cancer Center under the direction of principal investigator Ramiro Garzon, MD, Associate Professor. Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares moved down -7.00% in last trading session and was closed at $25.63, while trading in range of $25.45-$28.33. Karyopharm Therapeutics Inc (NASDAQ:KPTI) year to date performance is 11.82%.
IPC The Hospitalist Company (NASDAQ:IPCM) has earned an average rating of “Hold” from the ten analysts that are covering the stock, Analyst Ratings Network.com reports. Seven investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. IPC The Hospitalist Company Inc (NASDAQ:IPCM) weekly performance is -13.55%. On last trading day company shares ended up $41.66. IPC The Hospitalist Company Inc (NASDAQ:IPCM) distance from 50-day simple moving average is -17.65%. Analysts mean target price for the company is $56.77.